Zobrazeno 71 - 80
of 254
pro vyhledávání: '"Charles E. Geyer"'
Autor:
Stephen L. Jones, Juan Carlos Nicolas, Polly A. Niravath, Tejal Patel, Jenny C. Chang, X. Xu, S. Manne, Kai Sun, Charles E. Geyer, M. Niravath, Kartik Anand
Publikováno v:
Annals of Oncology. 31:S933
Autor:
Ying-Chih Lin, Sabine Seiler, Charles E. Geyer, Fernando Salvador Moreno, Peter C. Lucas, S. Loibl, C. Jackisch, A. Poklepovic, Priya Rastogi, Eleftherios P. Mamounas, Valentina Nekljudova, C Denkert, Norman Wolmark
Publikováno v:
Annals of Oncology. 31:S339
Autor:
Charles E. Geyer, Ellen Shrader, Prithviraj Bose, Maciej Kmieciak, Maria Quigley, John D. Roberts, Katie Strickler, Wen Wan, Mary Beth Tombes, H. Davis Massey, Danielle Shafer, Paul Dent, William P. McGuire, Andrew Poklepovic, Sarah W. Gordon, Laurence Booth, Richard G. Moran
Publikováno v:
Oncotarget
// Andrew Poklepovic 1, 2 , Sarah Gordon 2 , Danielle A. Shafer 1, 2 , John D. Roberts 1, 2, 7 , Prithviraj Bose 1, 2, 8 , Charles E. Geyer Jr. 1, 2 , William P. McGuire 1, 2 , Mary Beth Tombes 1 , Ellen Shrader 1 , Katie Strickler 1 , Maria Quigley
Autor:
Val Gebski, Paul de Souza, Ian C. Marschner, Sherene Loi, Chee Khoon Lee, Angelo Di Leo, Michael F. Press, Charles E. Geyer, David Cameron, Sarah J. Lord, John Simes, Stephen R. D. Johnston, Lucy Claire Davies, Catherine E. Ellis
Publikováno v:
Journal of Clinical Oncology. 34:936-944
Purpose We examined the prognostic and predictive value of serum human epidermal growth factor 2 (HER2) extracellular domain (sHER2) in patients with advanced breast cancer treated with lapatinib using data from three randomized trials. Patients and
Autor:
Charles E. Geyer, J Zujweski, Timothy F. Goggins, Jeffrey L. Berenberg, Daniel F. Hayes, M. Keane, Kathleen I. Pritchard, Adam Brufsky, JN Atkins, IA Mayer, Deborah Toppmeyer, KS Albain, GW Sledge, Virginia G. Kaklamani, E. A. Perez, Elizabeth Claire Dees, H. L. Gomez Moreno, John A. Olson, Joseph A. Sparano, DF Makower, Richard Gray, RP Reddi
Publikováno v:
Cancer Research. 76:P2-08
Background: The Trial Assigning Individualized Options for Treatment (TAILORx) is a prospective trial evaluating the role of endocrine therapy or chemoendocrine therapy in patients 18-75 years of age with estrogen receptor (ER)-positive, HER2-negativ
Autor:
Barry C. Lembersky, Charles E. Geyer, Edward H. Romond, Gong Tang, Joseph P. Costantino, Norman Wolmark, Jong-Hyeon Jeong, Alexander H.G. Paterson, Priya Rastogi, Reena S. Cecchini, Stewart J. Anderson, Sandra M. Swain
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 25:51-59
Background: Body mass index (BMI) has been associated with breast cancer outcomes. However, few studies used clinical trial settings where treatments and outcomes are consistently evaluated and documented. There are also limited data assessing how pa
Autor:
G. von Minckwitz, Thomas Boulet, T.P. Mamounas, Max S. Mano, Michael Untch, C. Wiese, C-S Huang, I. Schwaner, Norman Wolmark, Chunyan Song, Jenny C. Chang, Charles E. Geyer, S. Limentani, Thomas Hatschek, Kristina Lübbe, N. Loman, S. Loibl, D. Tesarowski, J-C. Thery
Publikováno v:
Annals of Oncology. 31:S48
Autor:
Mehra Golshan, Michael Untch, O. Metzger-Filho, Jens Bodo Houber, Stephanie M. Wong, William M. Sikov, Gunter von Minckwitz, David Maag, Sibylle Loibl, Joyce O'Shaughnessy, Hope S. Rugo, Norman Wolmark, Danielle Sullivan, Charles E. Geyer, Mark D. McKee
Publikováno v:
JAMA Surgery. 155:e195410
Importance Neoadjuvant systemic therapy (NST) is often administered to enable breast-conserving therapy (BCT) in stages II to III breast cancer. Objectives To prospectively evaluate the role of NST in conversion from BCT ineligibility to BCT eligibil
Autor:
D Lawerence Wickerham, Barry C. Lembersky, Thomas E. Seay, Hanna Bandos, James L. Wade, Stephen Chia, Edward C. McCarron, Norman Wolmark, Charles E. Geyer, Mark L. Graham, Gamini S. Soori, Sandra M. Swain, Priya Rastogi, Louis Fehrenbacher, Eleftherios P. Mamounas, Soonmyung Paik, Janice M. Walshe, Shaker R. Dakhil, Jeon Hyeon Jeong, Adam Brufsky
Publikováno v:
Cancer Research. 80:GS4-01
Background: In the NSABP B-42 trial we aimed to determine whether 5 yrs of letrozole (L) v placebo (P) improves DFS in patients (pts) who have completed 5 yrs of hormonal therapy (tx). 3966 postmenopausal pts with stage I-III, hormone-receptor+ BC, d
Autor:
William C. Wood, Jeffrey S. Abrams, John A. Olson, Robert Gray, C. Desbiens, Catalin Mihalcioiu, George W. Sledge, Elizabeth Claire Dees, Soonmyung Paik, Daniel F. Hayes, T.J. Saphner, Charles E. Geyer, Della F. Makower, Lynne I. Wagner, Joseph A. Sparano, MJ Ellis, Sunil Badve, T. Lively, Kathy S. Albain
Publikováno v:
Annals of Oncology. 30:v854
Background The recurrence score (RS) based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low. There is little information from prospective clinical